About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited (SUNPHARMA) has been publicly traded since 1996, making it a 30-year-old public company. It operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is headquartered in Mumbai, India and employs approximately 43,000 people. With a market capitalization of $4.3 trillion, SUNPHARMA is one of the largest publicly traded companies.
Key Statistics
- Current Price
- ₹1,801.60
- Market Cap
- ₹4.32T
- 52-Week High
- ₹1,851.20
- 52-Week Low
- ₹1,548.00
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
₹1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +5.44% | ₹1,708.60 | ₹1,801.60 |
| 2025 | -7.98% | ₹1,856.84 | ₹1,708.60 |
| 2024 | +51.11% | ₹1,228.82 | ₹1,856.84 |
| 2023 | +27.16% | ₹966.35 | ₹1,228.82 |
| 2022 | +19.74% | ₹807.06 | ₹966.35 |
| 2021 | +44.40% | ₹558.91 | ₹807.06 |
| 2020 | +38.20% | ₹404.44 | ₹558.91 |
| 2019 | +1.13% | ₹399.92 | ₹404.44 |
| 2018 | -24.40% | ₹528.99 | ₹399.92 |
| 2017 | -8.73% | ₹579.60 | ₹528.99 |
| 2016 | -23.09% | ₹753.57 | ₹579.60 |
| 2015 | -0.44% | ₹756.92 | ₹753.57 |
| 2014 | +45.92% | ₹518.74 | ₹756.92 |
| 2013 | +54.85% | ₹334.99 | ₹518.74 |
| 2012 | +48.87% | ₹225.02 | ₹334.99 |
| 2011 | +3.35% | ₹217.72 | ₹225.02 |
| 2010 | +61.98% | ₹134.41 | ₹217.72 |
| 2009 | +43.44% | ₹93.70 | ₹134.41 |
| 2008 | -10.95% | ₹105.23 | ₹93.70 |
| 2007 | +32.79% | ₹79.24 | ₹105.23 |
| 2006 | +45.05% | ₹54.63 | ₹79.24 |
| 2005 | +23.43% | ₹44.26 | ₹54.63 |
| 2004 | +87.87% | ₹23.56 | ₹44.26 |
| 2003 | +100.55% | ₹11.75 | ₹23.56 |
| 2002 | +5.88% | ₹11.09 | ₹11.75 |
| 2001 | +7.64% | ₹10.31 | ₹11.09 |
| 2000 | -4.82% | ₹10.83 | ₹10.31 |
| 1999 | +535.09% | ₹1.71 | ₹10.83 |
| 1998 | +24.61% | ₹1.37 | ₹1.71 |
| 1997 | -3.38% | ₹1.42 | ₹1.37 |
Valuation
SUNPHARMA currently trades at a trailing P/E ratio of 39.5, which is considered high relative to the broader market. The forward P/E of 31.7 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 5.6. The price-to-sales ratio is 7.6.
Dividends
Sun Pharmaceutical Industries Limited pays a dividend to shareholders with a current yield of 0.92%. This translates to $16.50 per share annually. The payout ratio of 35% indicates sustainable dividend coverage.
Risk & Volatility
SUNPHARMA has a beta of 0.12, indicating it is less volatile than the overall market. The stock's 52-week range is $1548.00 to $1851.20, and it currently trades near its 52-week high.
Analyst Ratings
Based on 37 analyst opinions, SUNPHARMA has a consensus "buy" rating. The average price target of $1976.35 suggests 9.7% upside from current levels.
Frequently Asked Questions
What does Sun Pharmaceutical Industries Limited do? ▼
Sun Pharmaceutical Industries Limited is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Mumbai, India.
What sector is SUNPHARMA in? ▼
SUNPHARMA operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
When did SUNPHARMA go public? ▼
Sun Pharmaceutical Industries Limited went public in 1996, making it a 30-year-old public company as of 2026.
How much would $1,000 invested in SUNPHARMA 5 years ago be worth today? ▼
A $1,000 investment in SUNPHARMA five years ago would be worth approximately $3,035 today, representing a 203.5% return.
Does SUNPHARMA pay dividends? ▼
Yes, Sun Pharmaceutical Industries Limited pays a dividend with a current yield of 0.92%, which is $16.5 per share annually.
What is SUNPHARMA's market cap? ▼
Sun Pharmaceutical Industries Limited has a market capitalization of $4.3 trillion, classifying it as a mega-cap company.
What is SUNPHARMA's P/E ratio? ▼
SUNPHARMA has a trailing P/E ratio of 39.5 and a forward P/E of 31.7, which measures how much investors are paying per dollar of earnings.
Is SUNPHARMA a buy, hold, or sell? ▼
Based on 37 opinions, SUNPHARMA has a consensus "buy" rating. The average price target is $1976.35.
Last updated: 3/14/2026